FLT3 and myelodysplastic syndrome: These differences are most pronounced in the Beat AML cohort, where the mutated genes dominating the male FLT3‐ITD‐negative subpopulation are associated with poor outcome and with myelodysplastic syndrome (MDS) and secondary AML [35].